Abstract 52P
Background
Post mastectomy adjuvant radiotherapy (RT) is a critical part in management of breast cancers. Left sided breast cancer cases are at higher risk of developing radiation induced cardiac morbidities. Increased radiation dose to the heart and lung may cause non-breast cancer related mortality and reduce the survival benefits from breast cancer RT. We designed a prospective clinical trial to examine the impact of CPAP on heart and lung during left sided post mastectomy radiotherapy.
Methods
24 left sided post mastectomy patients, after prior consent were included in this study. All patients were simulated in free breathing technique, followed by using CPAP (target pressure 10 to 15 cm of H20). Contouring was done using RTOG guideline. Heart and lung volumes were noted. IMRT virtual plans for both of these techniques were made for all patients using Monaco 5.51.10 software. Mean heart dose, Heart V25, Ipsilateral Lung mean dose, V5, V10, V20 were measured. Mean ± Std values were assessed using Students’ t-test.
Results
Compared to FB, CPAP showed significant difference. Mean heart distance from sternal notch was 6.2 cm and 7.2 cm ;p Value: 0.032 and Mean heart volumes were 354cc and 387cc in the CPAP and FB arms respectively;pValue: 0.665 . Mean left lung volumes were 1281 cc and 1398 cc respectively ;pValue 0.038 favouring CPAP arm. Similarly mean right lung volume of 1552 cc was significantly higher in CPAP arm compared to 1178 cc in FB arm (pValue : 0.041). Heart Dmean was found to be statistically better in CPAP arm (2.5 Gy) compared to FB arm (3.4 Gy) (p Value 0.020). Average V25 of heart was significantly superior in CPAP arm compared to FB arm (0.23% and 2.24% respectively,p Value 0.035). Heart Dmean was 3.1 Gy in CPAP arm compared to 3.7 Gy in FB arm ,pValue: 0.677. Similar result was found for heart V25. CPAP and FB Ipsilateral lung mean dose (6.69Gy and 6.32Gy, pValue: 0.62), Lung V5 (29% and 27.3%, p Value: 0.77), Lung V10 (16.3% and 16.4%, pValue: 0.78), Lung V20 (11.2% and 11.89%, p value 0.22) didn’t show statistical difference.
Conclusions
CPAP is an excellent tool for cardiac sparing in left sided post mastectomy breast cancer cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract